BioSpace News Archive

revi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients with pruritus in prurigo nodularis (PN).

Premier Research has again expanded its presence in the Asia-Pacific region to include South Korea, Singapore, and Taiwan.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer (NK) cell therapy™, today announced it has received a favorable response from the U.S. Food and Drug Administration (FDA) to its pre-Investigational New Drug (“pre-IND”) meeting package for the proposed Phase 2 trial of CytoSen’s adoptive NK cell therapy,

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

ortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting phase 2 clinical development in AD next year.

Volker Herrmann, MD, experienced commercial executive, appointed Chief Operating Officer and President

ViaCyte, Inc. today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum.

Medical Marijuana, Inc. today announced that its subsidiary Phyto Animal Health will be hosting Q&A events at two of IB Pet’s Southern California locations.

Medical Marijuana, Inc. subsidiary HempMeds® announced today that it will release a new topical hemp product, its 50mg Active Relief Roll-On, at the Cannabis World Congress & Business Exposition (CWCBE) in Los Angeles, CA.